Literature DB >> 10822376

Exogenous E2F expression is growth inhibitory before, during, and after cellular transformation.

T A Lee1, P J Farnham.   

Abstract

To gain insight into the tumor suppressor properties of E2F1, we investigated growth inhibition by the E2F family of transcription factors using a tissue culture model system. We first show that exogenous E2F expression causes an 80% decrease in NIH3T3 colony formation and activated c-Ha-Ras-mediated focus formation. Inhibition of Ras-mediated transformation was dependent upon E2F DNA binding activity but did not require amino- or carboxy-terminal E2F1 protein interaction domains. Because E2F upregulation has been suggested to be associated with a neoplastic phenotype, it was possible that increased E2F activity would not be inhibitory to previously transformed cells. However, we found that exogenous E2F was also inhibitory to growth of NIH3T3 cells previously transformed by Ras or Neu. Further characterization revealed that exogenous E2F expression is inhibitory at very early times after transfection, causing dramatic losses in transfected cell populations. Interestingly, those few cells which do establish appear to be unaffected by the overexpressed E2F. Therefore, we propose that increased E2F activity may only be tolerated in a subset of cells which have acquired specific alterations that are dominant over E2F-mediated growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822376     DOI: 10.1038/sj.onc.1203556

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Use of chromatin immunoprecipitation to clone novel E2F target promoters.

Authors:  A S Weinmann; S M Bartley; T Zhang; M Q Zhang; P J Farnham
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

2.  Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis.

Authors:  Amy S Weinmann; Pearlly S Yan; Matthew J Oberley; Tim Hui-Ming Huang; Peggy J Farnham
Journal:  Genes Dev       Date:  2002-01-15       Impact factor: 11.361

3.  Arginine methylation controls growth regulation by E2F-1.

Authors:  Er-Chieh Cho; Shunsheng Zheng; Shonagh Munro; Geng Liu; Simon M Carr; Jutta Moehlenbrink; Yi-Chien Lu; Lindsay Stimson; Omar Khan; Rebecca Konietzny; Joanna McGouran; Amanda S Coutts; Benedikt Kessler; David J Kerr; Nicholas B La Thangue
Journal:  EMBO J       Date:  2012-02-10       Impact factor: 11.598

4.  Genome-wide analysis of transcription factor E2F1 mutant proteins reveals that N- and C-terminal protein interaction domains do not participate in targeting E2F1 to the human genome.

Authors:  Alina R Cao; Roman Rabinovich; Maoxiong Xu; Xiaoqin Xu; Victor X Jin; Peggy J Farnham
Journal:  J Biol Chem       Date:  2011-02-10       Impact factor: 5.157

5.  Aberrant promoter methylation status is associated with upregulation of the E2F4 gene in breast cancer.

Authors:  Farman Ullah Farman; Farhan Haq; Noor Muhammad; Nawab Ali; Hazir Rahman; Muhammad Saeed
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

6.  Comparative analysis of E2F family member oncogenic activity.

Authors:  Chunxia Chen; Andrew D Wells
Journal:  PLoS One       Date:  2007-09-19       Impact factor: 3.240

7.  The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells.

Authors:  Ji Sun; Hong Li; Qi Huo; Meiling Cui; Chao Ge; Fangyu Zhao; Hua Tian; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  Oncotarget       Date:  2016-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.